79353016 - VISCOFAN FIBERCOLL-FLEX

Information

• Trademark
• 79353016

• Source

• Serial Number

  79353016

• Registration Number

  7497685

• International Classifications

  • 1 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry
  • 2 - Paints, varnishes, lacquers
  • 5 - Pharmaceutical and veterinary preparations

• Filing Date

  July 28, 2022
  2 years ago

• Registration Date

  September 10, 2024
  5 months ago

• Transaction Date

  February 20, 2025
  8 days ago

• Status Date

  September 10, 2024
  5 months ago

• Published for Opposition Date

  June 25, 2024
  8 months ago

• Location Date

  September 09, 2024
  5 months ago

• Status Code

  700

• Current Location

  FILE REPOSITORY (FRANCONIA)

  Employee Name

  TWOHIG,SHANNON MARIE

• Attorney Docket Number

  41412/119

  Attorney Name

  Douglas A. Miro

• Owners

  • Viscofan S.A.

Case File Statements

• GS0051: Hydrogels for medical, veterinary and pharmaceutical purposes for cellular biology applications; hydrogels for cell growth, cell growth and transplantation, assays based on cells, cancer cell research, regenerative medicine, stem cell growth and drug delivery for medical use; hydrogels for cell culture for medical, veterinary and pharmaceutical purposes; hydrogels for cell growth for medical, veterinary and pharmaceutical purposes; cell culture media for medical use; nutritional agents for processing living cells, namely, cell culture media growth factors contained within a reservoir; synthetic peptides for the treatment of degenerated hard and soft tissues; synthetic peptide derivativesfor the treatment of degenerated hard and soft tissues; cells for medical, veterinary and pharmaceutical use; cells or tissues in hydrogels for medical, veterinary or pharmaceutical use; pharmaceutical preparations for use in 3D bio-printing of tissues and organs; pharmaceutical preparations with other materials and ingredients for use in 3D bio-printing of tissues and organs; regenerative tissue being pharmaceutical preparations for hard and soft tissue regeneration; cells for medical use; allogeneic human tissue; living cells for medical use; implants containing living tissue; implantable living tissue materials for use in guided tissue regeneration; skin grafts; surgical implants formed by living tissue; surgical implants of living tissues derived from stem cells; transdermal patches for the creation of skin for prostheses and skin grafts; living tissue for transplants; engineered biological tissues and organs, namely, human and animal cardiovascular, pulmonary, digestive, hepatobiliary, urological, renal, endocrine, epithelial, muscular, and nervous tissues and organs, for medical purposes; biological molecules being implants comprising living tissue to assist in tissue engineering, namely, hard and soft tissue regeneration; hemostatic gel matrix preparations for wound treatment; natural biomaterials for the growth of bones, blood and tissues for medical purposes; pharmaceutical products for the regeneration of tissues, for the repair of tissues, for the treatment of tissues, whether human or animal, namely, 3D implants for hard and soft tissue regeneration combining bioinks and biological materials; pharmaceutical preparations for the treatment of diseases of bones, cartilages, blood vessels, nerve cell degeneration, tendon and ligament degeneration, retinal degeneration, kidney degeneration; soft tissue degenerations, for diseases with abnormal cell growth, namely, formulated bioinks for hard and soft tissue regeneration combining bioinks and biological materials with a pharmaceutical effect; natural biomaterial for bone filling; natural biomaterial for cartilage filling; biological tissue cultures for medical use; biological tissue cultures for medical purposes; biological tissue grafts; bone and skin biological tissues impregnated with oxygen lines for tissue constructs applicable for increasing the cell survival in tissue intended for subsequent implants; gene therapy products, namely, genetically modified tissues for the transplant thereof; implantable stents composed primarily of living tissue to maintain the structure of the tissue; natural biomaterial for bone and tissue growth for medical purposes
• GS0021: Inks of biological origin for printers; inks of biological origin for 3D printers
• GS0011: Biological materials or preparations for 3D printers, namely, bioinks, bioprinting kits comprised of collagen, biological printed tissues other than for medical or veterinary purposes; hydrogels for cell culture not for medical or veterinary purposes; hydrogels for cell growth not for medical or veterinary purposes; cell culture media other than for medical or veterinary use; nutritional agents for processing living cells other than for medical use, namely, cell culture media within a reservoir for growth factors; culture media for microbiology for laboratory use; reagents for scientific and medical research; synthetic peptides not for pharmaceutical purposes, namely, peptide substrates used in analyzing and detecting certain toxins for laboratory or research use; synthetic peptide derivatives not for pharmaceutical purposes, namely, peptide substrates used in analyzing and detecting certain toxins for laboratory or research use; cells other than for medical, veterinary or pharmaceutical use; cells or tissues in hydrogels other than for medical, veterinary or pharmaceutical use; biologically compatible polymers, specifically hydrogels used to produce polymer networks used in the manufacture of engineered living tissues for medical, scientific and non-scientific purposes, namely, tissue implants, organoids, tissue models; cell culture media for use in the biotechnological industry for laboratory use; cell culture media for use in non-medical research laboratories; biological preparations for use in cell culture, other than for medical and veterinary purposes; engineered living tissues and tissue arrays, namely, human and animal organs, connective tissue, epithelial tissue, muscular tissue and nervous tissue, and tissue arrays, for use in scientific and medical research; biologically compatible materials, specifically, hydrogels used to create polymeric networks used in the manufacture of living tissues for laboratory use; proteins in the form of raw materials for scientific and medical research

Case File Event Statements

• 10/21/2022 - 2 years ago

  2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS

• 10/20/2022 - 2 years ago

  1 - SN ASSIGNED FOR SECT 66A APPL FROM IB Type: REPR

• 10/25/2022 - 2 years ago

  3 - APPLICATION FILING RECEIPT MAILED Type: MAFR

• 2/23/2023 - 2 years ago

  4 - ASSIGNED TO EXAMINER Type: DOCK

• 2/28/2023 - 2 years ago

  5 - NON-FINAL ACTION WRITTEN Type: CNRT

• 3/1/2023 - 2 years ago

  6 - NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW Type: RFCR

• 4/22/2023 - a year ago

  7 - REFUSAL PROCESSED BY MPU Type: RFRR

• 4/22/2023 - a year ago

  8 - NON-FINAL ACTION MAILED - REFUSAL SENT TO IB Type: RFCS

• 5/17/2023 - a year ago

  9 - REFUSAL PROCESSED BY IB Type: RFNT

• 10/20/2023 - a year ago

  10 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA

• 10/20/2023 - a year ago

  11 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA

• 10/20/2023 - a year ago

  12 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME

• 11/29/2023 - a year ago

  13 - FINAL REFUSAL WRITTEN Type: CNFR

• 11/29/2023 - a year ago

  14 - FINAL REFUSAL E-MAILED Type: GNFR

• 11/29/2023 - a year ago

  15 - NOTIFICATION OF FINAL REFUSAL EMAILED Type: GNFN

• 5/9/2024 - 9 months ago

  22 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME

• 3/1/2024 - 12 months ago

  16 - NEW REPRESENTATIVE AT IB RECEIVED Type: NREP

• 3/20/2024 - 11 months ago

  18 - NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB Type: OPNS

• 3/20/2024 - 11 months ago

  17 - NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB Type: OPNR

• 4/8/2024 - 10 months ago

  19 - NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB Type: OPNX

• 5/9/2024 - 9 months ago

  21 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA

• 5/9/2024 - 9 months ago

  20 - TEAS REQUEST FOR RECONSIDERATION RECEIVED Type: ERFR

• 5/17/2024 - 9 months ago

  23 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA

• 6/5/2024 - 8 months ago

  24 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Type: NONP

• 6/11/2024 - 8 months ago

  26 - NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB Type: OPNS

• 6/25/2024 - 8 months ago

  27 - PUBLISHED FOR OPPOSITION Type: PUBO

• 6/25/2024 - 8 months ago

  28 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB

• 6/11/2024 - 8 months ago

  25 - NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB Type: OP2R

• 7/1/2024 - 8 months ago

  29 - NOTIFICATION PROCESSED BY IB Type: GPNX

• 9/10/2024 - 5 months ago

  30 - REGISTERED-PRINCIPAL REGISTER Type: R.PR

• 2/19/2025 - 9 days ago

  33 - FINAL DISPOSITION PROCESSED Type: FIMP

• 2/20/2025 - 8 days ago

  34 - FINAL DISPOSITION NOTICE SENT TO IB Type: FICS

• 12/10/2024 - 2 months ago

  32 - FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB Type: FICR

• 9/10/2024 - 5 months ago

  31 - NOTICE OF REGISTRATION CONFIRMATION EMAILED Type: NRCC